DelveInsight’s “Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology and Market Size Forecast-2020” Reports provides an overview of the disease and global market size of the Idiopathic pulmonary fibrosis (IPF) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Idiopathic pulmonary fibrosis (IPF) from 2010-2020.Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. The major types of this condition are hemophilia A (also known as classic hemophilia or factor VIII deficiency) and hemophilia B (also known as Christmas disease or factor IX deficiency). Although the two types have very similar signs and symptoms, they are caused by mutations in different genes. Gene therapy might eventually help people with hemophilia begin producing their own clotting factor, alleviating the need for or reducing the number of weekly infusions.
Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
It also provides Market size of Idiopathic pulmonary fibrosis (IPF) for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
Note*: This report requires 5-10 business days to complete.